Healthcare Business Recap: Pfizer’s Problem, BioSante Pharmaceuticals Positive Study
Studies of Pill-Plus oral contraceptive are creating good news for BioSante Pharmaceuticals (NASDAQ:BPAX) as it reported a positive outcome. If the product is introduced in the U.S., BioSante stands to receive royalties from its sales.
The much acclaimed rheumatory arthritis treatment Tofacitnib, made by Pfizer (NYSE:PFE), has its share of problems. Most doctors (55 percent) responding to a survey say that they will not replace a current drug they prescribe with Tofacitnib, and 96 percent of insurers will not do the same in their coverage plans.
Biotech firms that currently sell diagnostic devices, such as Abbot (NYSE:ABT), Myriad Genetics (NASDAQ:MYGN), and Roche (RHHBY.PK), could be negatively impacted by the Supreme Court’s decision rejecting Prometheus Labs’ (NSRGY.PK) testing patents.
China will be the location of launches of more than a dozen different Eli Lilly (NYSE:LLY) products in the next five years, as that company seeks to become the fastest growing pharmaceuticals brand in the country. Treatment of diabetes will be concentrated upon in particular, as that market is projected to expand to $2.1 billion by 2019.
Cambia Heath selects Catalyst Health Solutions (NASDAQ:CHSI) as exclusive provider of pharmacy benefit management services for one of its units, and Catalyst raises its full-year revenue guidance accordingly. Oppenheimer remarks positively that the appointment might place CHSI on track to beat its 2013 goal of doubling new business from 2011’s $400 million.
Don’t Miss: How Will the GOP Cut Spending By $5.3 Trillion?